

Highlights of This Issue 7205

SPECIAL FEATURES

CCR Translations

- 7207 **Micromanaging the Classification of Colon Cancer: The Role of the microRNAome**
Eduardo Vilar, Josep Taberner, and Stephen B. Gruber
See article p. 7283 and Balaguer et al., Clin Cancer Res, vol. 17(20), p. 6239–49

- 7210 **Disentangling the Myeloma Web**
Giovanni Tonon and Kenneth C. Anderson
See article p. 7402

CCR New Strategies

- 7213 **New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers**
Takaaki Sasaki and Pasi A. Jänne

Molecular Pathways

- 7219 **β 1-Integrin: A Potential Therapeutic Target in the Battle against Cancer Recurrence**
Dalit Barkan and Ann F. Chambers

- 7224 **Cancer Stem Cells: Targets and Potential Biomarkers for Radiotherapy**
Mechthild Krause, Ala Yaromina, Wolfgang Eicheler, Ulrike Koch, and Michael Baumann

HUMAN CANCER BIOLOGY

- 7230 **Tumor-Associated Macrophages Promote Angiogenesis and Melanoma Growth via Adrenomedullin in a Paracrine and Autocrine Manner**
Peiwen Chen, Yujie Huang, Rosabel Bong, Yanping Ding, Nan Song, Xiaofeng Wang, Xiaomin Song, and Yongzhang Luo

- 7240 **Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine**
Tobias Meißner, Anja Seckinger, Thierry Rème, Thomas Hielscher, Thomas Möhler, Kai Neben, Hartmut Goldschmidt, Bernard Klein, and Dirk Hose

- 7248 **Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites**

Mei Zhao, Daisuke Sano, Curtis R. Pickering, Samar A. Jasser, Ying C. Henderson, Gary L. Clayman, Erich M. Sturgis, Thomas J. Ow, Reuben Lotan, Thomas E. Carey, Peter G. Sacks, Jennifer R. Grandis, David Sidransky, Nils Erik Heldin, and Jeffrey N. Myers

- 7265 **A Novel Aldehyde Dehydrogenase-3 Activator Leads to Adult Salivary Stem Cell Enrichment *In Vivo***

Alice Banh, Nan Xiao, Hongbin Cao, Che-Hong Chen, Peiwen Kuo, Trevor Krakow, Brindha Bavan, Brian Khong, Mike Yao, Chi Ha, Michael J. Kaplan, Davud Sirjani, Kristin Jensen, Christina S. Kong, Daria Mochly-Rosen, Albert C. Koong, and Quynh-Thu Le

- 7273 **Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?**

Sally M. Hunter, Michael S. Anglesio, Raghwa Sharma, C. Blake Gilks, Nataliya Melnyk, Yoke-Eng Chiew, Anna deFazio for the Australian Ovarian Cancer Study Group, Teri A. Longacre, Anna deFazio, David G. Huntsman, Kylie L. Gorringer, and Ian G. Campbell

- 7283 **Complex Patterns of Altered MicroRNA Expression during the Adenoma-Adenocarcinoma Sequence for Microsatellite-Stable Colorectal Cancer**

Angela N. Bartley, Hui Yao, Bedia A. Barkoh, Cristina Ivan, Bal M. Mishra, Asif Rashid, George A. Calin, Rajyalakshmi Luthra, and Stanley R. Hamilton
See commentary p. 7207

- 7294 **Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition**

Kai Zhu, Zhi Dai, Qi Pan, Zheng Wang, Guo-Huan Yang, Lei Yu, Zhen-Bin Ding, Guo-Ming Shi, Ai-Wu Ke, Xin-Rong Yang, Zhong-Hua Tao, Yi-Ming Zhao, Yi Qin, Hai-Ying Zeng, Zhao-You Tang, Jia Fan, and Jian Zhou

7303 **Gene Expression Differences between Colon and Rectum Tumors**
Rebeca Sanz-Pamplona, David Cordero, Antonio Berenguer, Flavio Lejbkowitz, Hedy Rennert, Ramon Salazar, Sebastiano Biondo, Xavier Sanjuan, Miguel A. Pujana, Laura Rozek, Thomas J. Giordano, Ofer Ben-Izhak, Hector I. Cohen, Philip Trougouboff, Jacob Bejhar, Yanina Sova, Gad Rennert, Stephen B. Gruber, and Victor Moreno

CANCER THERAPY: PRECLINICAL

7313 **Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies**
Edmund C. Lee, Michael Fitzgerald, Bret Bannerman, Jill Donelan, Kristen Bano, Jennifer Terkelsen, Daniel P. Bradley, Ozlem Subakan, Matthew D. Silva, Ray Liu, Michael Pickard, Zhi Li, Olga Tayber, Ping Li, Paul Hales, Mary Carsillo, Vishala T. Neppalli, Allison J. Berger, Erik Kupperman, Mark Manfredi, Joseph B. Bolen, Brian Van Ness, and Siegfried Janz

7324 **Inhibition of the Notch-Hey1 Axis Blocks Embryonal Rhabdomyosarcoma Tumorigenesis**
Brian C. Belyea, Sarasija Naini, Rex C. Bentley, and Corinne M. Linaudic

7337 **Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance**
Kristy J. Gotink, Henk J. Broxterman, Mariette Labots, Richard R. de Haas, Henk Dekker, Richard J. Honeywell, Michelle A. Rudek, Laurens V. Beerepoot, René J. Musters, Gerrit Jansen, Arjan W. Griffioen, Yehuda G. Assaraf, Roberto Pili, Godefridus J. Peters, and Henk M.W. Verheul

7347 **Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells**
Warren Fiskus, Srđan Verstovsek, Taghi Manshouri, Rekha Rao, Ramesh Balusu, Sreedhar Venkannagari, Narasimha Rao Nalabothula, Kyungsoo Ha, Jacqueline E. Smith, Stacey L. Hembruff, Sunil Abhyankar, Joseph McGuirk, and Kapil N. Bhalla

7359 **Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma**
Rong Wu, Tom C. Hu, Alnawaz Rehemtulla, Eric R. Fearon, and Kathleen R. Cho

7373 **Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma**
Steven I. Park, Jaideep Sheno, Shani M. Frayo, Donald K. Hamlin, Yukang Lin, D. Scott Wilbur, Patrick S. Stayton, Nural Orgun, Mark Hylarides, Franz Buchegger, Aimee L. Kenoyer, Amanda Axtman, Ajay K. Gopal, Damian J. Green, John M. Pagel, and Oliver W. Press

7383 **Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts**
Tooba A. Cheema, Ryuichi Kanai, Geon Woo Kim, Hiroaki Wakimoto, Brent Passer, Samuel D. Rabkin, and Robert L. Martuza

7394 **ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors**
Johannes M. Heuckmann, Michael Hölzel, Martin L. Sos, Stefanie Heynck, Hyatt Balke-Want, Mirjam Koker, Martin Peifer, Jonathan Weiss, Christine M. Lovly, Christian Grütter, Daniel Rauh, William Pao, and Roman K. Thomas

IMAGING, DIAGNOSIS, PROGNOSIS

7402 **The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma**
Luca Agnelli, Mattia Forcato, Francesco Ferrari, Giacomo Tuana, Katia Todoerti, Brian A. Walker, Gareth J. Morgan, Luigia Lombardi, Silvio Biciato, and Antonino Neri
See commentary p. 7210

7413 **CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients**
Ilaria Iacobucci, Anna Ferrari, Annalisa Lonetti, Cristina Papayannidis, Francesca Paoloni, Stefania Trino, Clelia Tiziana Storlazzi, Emanuela Ottaviani, Federica Cattina, Luciana Impera, Maria Chiara Abbenante, Marco Vignetti, Antonella Vitale, Leonardo Potenza, Stefania Paolini, Simona Soverini, Fabrizio Pane, Mario Luppi, Robin Foà, Michele Baccarani, and Giovanni Martinelli

7424 | **Molecular Imaging of TGF β -Induced Smad2/3 Phosphorylation Reveals a Role for Receptor Tyrosine Kinases in Modulating TGF β Signaling**
Shyam Nyati, Katrina Schinske, Dipankar Ray, Mukesh Nyati, Brian Dale Ross, and Alnawaz Rehemtulla

7462 | **Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma**
John Fruehauf, Jose Lutzky, David McDermott, Charles K. Brown, Jean-Baptiste Meric, Brad Rosbrook, David R. Shalinsky, Katherine F. Liaw, Andreas G. Niethammer, Sinil Kim, and Olivier Rixe

CANCER THERAPY: CLINICAL

7440 | **Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma**
Geoffrey R. Weiss, William W. Grosh, Kimberly A. Chianese-Bullock, Yingdong Zhao, Hui Liu, Craig L. Slingluff Jr, Francesco M. Marincola, and Ena Wang

7451 | **Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma**
Kevin B. Kim, Jason Chesney, Douglas Robinson, Humphrey Gardner, Michael M. Shi, and John M. Kirkwood


PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

7470 | **Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy**
Aziz Zaanani, Jean-François Fléjou, Jean-François Emile, Gaëtan Des Guetz, Peggy Cuilliere-Dartigues, David Malka, Cédric Lecaille, Pierre Validire, Christophe Louvet, Philippe Rougier, Aimery de Gramont, Franck Bonnetain, Françoise Praz, and Julien Taieb

7479 | **Acknowledgment to Reviewers**

ABOUT THE COVER

This image demonstrates unique genomic aberrations in adjacent stroma and epithelium in a benign serous ovarian cystadenofibroma. Pseudocolored FISH probes for chromosomes 12 (orange and green) and 15 (blue) identified clusters of epithelial cells with balanced tetrasomy alongside fibroblast cells triploid for chromosome 12. Nuclei were counterstained with DAPI. For details, see the article by Hunter and colleagues on page 7273 of this issue.



Clinical Cancer Research

17 (23)

Clin Cancer Res 2011;17:7205-7501.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/17/23>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/17/23>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.